For women with early-stage gynecologic cancers, we offer aggressive treatments with the goal of curing the cancer. Managing the toxic effects of these therapies is crucial—but cure is often possible. When a cure is much less likely because the cancer is more advanced, we focus primarily on controlling the cancer and taking steps to preserve the woman’s quality of life. We also offer new, investigational therapies to people with cancer that has recurred (reappeared).
In addition to the daily care of women with gynecologic cancers, I run clinical trials that are testing new, targeted drugs, and oversee a small research laboratory looking for answers to such questions as why certain tumors resist drug treatment and how genes can affect the development of tumors.
In my work on a national scale, I serve on committees for the National Cancer Institute and play a role on the editorial boards of such publications as Investigational New Drugs, Gynecologic Oncology, and Clinical Cancer Research. Currently I am the associate editor of the Journal of Clinical Oncology. Over the years, I have authored (or co-authored) more than 150 journal articles on such topics as ovarian cancer biology and the results of clinical investigations, from the earliest stages of drug development to randomized phase III trials.